AQR Capital Management LLC Has $36.61 Million Holdings in Humana Inc. (NYSE:HUM)

AQR Capital Management LLC decreased its position in Humana Inc. (NYSE:HUM) by 87.8% during the 2nd quarter, Holdings Channel.com reports. The firm owned 97,986 shares of the insurance provider’s stock after selling 702,568 shares during the period. AQR Capital Management LLC’s holdings in Humana were worth $36,612,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in HUM. CarsonAllaria Wealth Management Ltd. grew its holdings in Humana by 111.4% in the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after buying an additional 39 shares in the last quarter. Hantz Financial Services Inc. acquired a new position in shares of Humana in the second quarter valued at about $35,000. Family Firm Inc. acquired a new position in shares of Humana in the second quarter valued at about $37,000. Hollencrest Capital Management acquired a new stake in Humana in the 2nd quarter worth about $40,000. Finally, Riverview Trust Co bought a new stake in Humana in the 2nd quarter valued at about $44,000. Institutional investors own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Piper Sandler started coverage on shares of Humana in a report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 target price on the stock. JPMorgan Chase & Co. lifted their price objective on Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a report on Wednesday, August 21st. Morgan Stanley started coverage on Humana in a report on Monday, June 24th. They set an “equal weight” rating and a $374.00 target price on the stock. Truist Financial boosted their price target on Humana from $355.00 to $400.00 and gave the company a “hold” rating in a research note on Monday, July 15th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $395.00 price objective on shares of Humana in a research note on Friday, September 20th. Thirteen equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $398.70.

Humana Trading Up 2.1 %

Shares of HUM stock opened at $319.57 on Friday. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $38.51 billion, a P/E ratio of 19.90, a P/E/G ratio of 2.44 and a beta of 0.50. Humana Inc. has a twelve month low of $298.61 and a twelve month high of $530.54. The stock’s fifty day simple moving average is $349.94 and its 200 day simple moving average is $344.48.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same quarter last year, the business earned $8.94 EPS. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. As a group, sell-side analysts predict that Humana Inc. will post 16.01 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.11%. Humana’s dividend payout ratio is 22.04%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.